Given that TMEM97 is integral to regulation of Niemann–Pick disease type C1, this also paves the way to understanding further whether S2R modulators or genetic manipulation of TMEM97 may be fruitful in ameliorating aspects of Niemann–Pick disease type C. As pharmacological agents directed at S2R are developed, it is likely that effective therapeutics for a host of indications will emerge, as several recent reviews discuss [87,179,180,181]. This evidence concerns the gene TMEM97 and Niemann-Pick disease type C.